Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years

Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years

Abstract Background and purpose The purpose of this study was to evaluate the outcomes of elderly patients (aged ≥75 years) with newly diagnosed glioblastoma (GBM), who were treated with hypofractionated radiotherapy comprising 45 Gy in 15 fractions combined with temozolomide (TMZ) or TMZ and bevaci...

Full description

Bibliographic Details
Main Authors: Makoto Ohno, Yasuji Miyakita, Masamichi Takahashi, Hiroshi Igaki, Yuko Matsushita, Koichi Ichimura, Yoshitaka Narita
Format: Article
Language:English
Published: BMC 2019-11-01
Series:Radiation Oncology
Subjects:
Elderly glioblastoma
Hypofractionated radiotherapy
Temozolomide
Bevacizumab
Vulnerability
Online Access:http://link.springer.com/article/10.1186/s13014-019-1389-7

Internet

http://link.springer.com/article/10.1186/s13014-019-1389-7

Similar Items